Physician profile
Mary A Gibson
NPI 1346301918
$1,463.93
in general payments reported to CMS, 2019-2025
22 companies · $565 in 2025
The $565 reported for 2025 was more than what 84% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $100 · 2023: $307 · 2024: $330 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $309.13 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lilly USA, LLC | $171.43 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Vanda Pharmaceuticals INC. | $157.46 | 2024-2025 | Fanapt |
| Lundbeck LLC | $135.25 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.61 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $69.06 | 2024-2025 | Trintellix |
| Electromed, INC. | $68.45 | 2022-2024 | Smartvest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.29 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Amgen INC. | $44.91 | 2023-2024 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $37.25 | 2025 | Cobenfy |
| Exact Sciences Corporation | $36.07 | 2025 | The Cologuard Plus Collection Kit |
| Philips North America LLC | $29.77 | 2022-2023 | |
| Alkermes, INC. | $29.54 | 2025 | Aristada, Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.41 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $20.00 | 2023 | Ingrezza |
| Medtronic, INC. | $19.13 | 2022 | |
| Pfizer INC. | $18.41 | 2023 | |
| Lucid Diagnostics INC. | $16.30 | 2022 | |
| Abbvie INC. | $12.72 | 2022 | |
| Corium, LLC | $4.74 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.